AML cytopathologically confirmed, except APL
Item
patients with cytopathologically confirmed diagnosis of aml according to who criteria, excluding acute promyelocytic leukemia.
boolean
C0023467 (UMLS CUI [1,1])
C0456521 (UMLS CUI [1,2])
C0023487 (UMLS CUI [2])
first relapsed AML
Item
first relapsed aml
boolean
C0023467 (UMLS CUI [1,1])
C0277556 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,3])
refractory aml
Item
primary refractory aml defined as failure to respond to initial induction chemotherapy (no cr) or recurrence within 6 months of initial cr.
boolean
C0023467 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
age
Item
age more than 18 years
boolean
C0001779 (UMLS CUI [1])
ECOG
Item
ecog performance status < 2
boolean
C1520224 (UMLS CUI [1])
deacetylase inhibitor
Item
prior treatment with deacetylase inhibitor
boolean
C1512474 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
investigational agent
Item
concurrent therapy with any other investigational agent
boolean
C1875319 (UMLS CUI [1,1])
C0009429 (UMLS CUI [1,2])
doxorubicin cumulative dose
Item
patients who have received cumulative doses (or its equivalent to other anthracyclines) of more than 360 mg/m2 of doxorubicin will be excluded from the study.
boolean
C0013089 (UMLS CUI [1,1])
C2986497 (UMLS CUI [1,2])
cns leukemia
Item
clinical symptoms suggesting cns leukemia
boolean
C1332884 (UMLS CUI [1,1])
C1457887 (UMLS CUI [1,2])
LVEF
Item
lvef below 45% other protocol-defined inclusion/exclusion criteria may apply
boolean
C0428772 (UMLS CUI [1])